Navigation Links
MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Date:10/31/2007

Company Provides Revised Timing on Interim Celgosivir Viral Kinetics Study

Data

VANCOUVER and SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases will present at the Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference being held at the New York Palace Hotel in New York, NY on November 5-7, 2007. Jim DeMesa, M.D., President & CEO is scheduled to present on Monday, November 5 at 4:45 p.m. EST in the Holmes I room.

As part of an overall corporate update, Dr. DeMesa will highlight the following:

- Omigard(TM) - a partnered Phase III product candidate for the

prevention of catheter-related infections

- Celgosivir - a Phase II product candidate for treating chronic

hepatitis C virus infections

- CLS001 - recent Phase II results from our partnered topical treatment

for rosacea.

Additionally, interim 4-week data expected in October from a Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection are delayed due to sample analysis not being completed at a contract research organization. Results will be reported when available, which is now anticipated to be in November.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II and preclinical), the prevention of catheter-related infections (Phase III) and the treatment of dermatological diseases (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at http://www.migenix.com.

"Jim DeMesa"

------------

James M. DeMesa, M.D.

President & CEO

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, and forward-looking information within the meaning of applicable securities laws in Canada, (collectively referred to as "forward-looking statements"). Statements, other than statements of historical fact, are forward-looking statements. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other things contemplated by the forward-looking statements will not occur.

Although our management believes that the expectations represented by such forward-looking statements are reasonable, there is significant risk that the forward-looking statements may not be achieved, and the underlying assumptions thereto will not prove to be accurate. Forward-looking statements in this news release include, but are not limited to, statements concerning our expectations for: interim 4-week data from a Phase II viral kinetics combination study of celgosivir now being anticipated in November.

With respect to the forward-looking statements contained in this news release, we have made numerous assumptions regarding, among other things: the contract organization's ability to complete the sample analysis and the completion of the interim 4-week data analysis being in November 2007.

Actual results or events could differ materially from the plans, intentions and expectations expressed or implied in any forward-looking statements, including the underlying assumptions thereto, as a result of numerous risks, uncertainties and other factors including: dependence on corporate collaborations; uncertainties related to early stage of technology and product development; and potential delays. Certain of these factors and other factors are described in detail in the Company's Annual Information Form and Annual Report on Form 20-F for and other filings with the Canadian securities regulatory authorities and the U.S. Securities & Exchange Commission.

Forward-looking statements are based on our current expectations and MIGENIX assumes no obligations to update such information to reflect later events or developments.

The Toronto Stock Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of this release.

CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666 Ext. 233, aayres@migenix.com; Dian Griesel, Ph.D., Investor Relations Group, Tel: (212) 825-3210, Theproteam@aol.com


'/>"/>
SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , ... September 25, 2017 , ... Throughout the month ... Project Verified label at over 13,000 stores nationwide, and industry expert David Carter is ... Now that Congress has passed the GMO labeling bill, demand for non-GMO foods and ...
(Date:9/25/2017)... , ... September 25, 2017 , ... ... by a third-party auditor, MindFlow Design has been found to provide product ... start-ups or Fortune 500 companies, our clients have a lot at ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... colleague Dr. Justin Zalewsky in offering LANAP® and LAPIP™ laser treatments. Drs. Hoge ... True Regeneration™ to patients, a minimally invasive and less painful option that produces ...
(Date:9/21/2017)... ... , ... Dr. Greg Leyer, Chief Scientific Officer of UAS Labs, will be ... at 12:10pm in the Probiotics Resource Center, Mandalay Bay Expo Hall. , “I ... probiotics have shown impressive data in areas outside the gut including heart health, Vitamin ...
Breaking Biology Technology:
(Date:6/30/2017)... 2017 Today, American Trucking Associations announced ... face and eye tracking software, became the newest ... "Artificial intelligence and advanced sensing ... a driver,s attentiveness levels while on the road.  ... detect fatigue and prevent potential accidents, which could ...
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
Breaking Biology News(10 mins):